A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile

Anaerobe

Volumn 40, Issue , 2016, Pages 10-14

  Endres, Bradley T ^a   Bassères, Eugénie ^a   Memariani, Ali ^b   Chang, Long ^a   Alam, M Jahangir ^a   Vickers, Richard J ^c   Kakadiaris, Ioannis A ^b   Garey, Kevin W ^a  

^a Department of Pharmacy Practice and Translational Research ^*  (United States)

^b University of Houston   (United States)

^c SUMMIT PLC   (United Kingdom)

Author keywords

Antibiotics; Clostridium difficile; Fidaxomicin; Metronidazole; Ridinilazole; Scanning electron microscopy; Vancomycin

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; RIDINILAZOLE; VANCOMYCIN; AGAR; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CULTURE MEDIUM;

ARTICLE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; IMAGE ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHENOTYPE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; CELL WALL; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECTS; FLUORESCENCE IMAGING; MICROBIAL SENSITIVITY TEST; PROCEDURES; ULTRASTRUCTURE;

AGAR; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CELL WALL; CLOSTRIDIUM DIFFICILE; CULTURE MEDIA; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; OPTICAL IMAGING; VANCOMYCIN;

EID: 84964389861     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2016.04.013     Document Type: Article

References (23)

1. Koo H.L., Garey K.W., Dupont H.L. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin. Investig. Drugs 2010, 19:825-836.
2. Shah D., Dang M.D., Hasbun R., Koo H.L., Jiang Z.D., DuPont H.L., et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev. Anti Infect. Ther. 2010, 8:555-564.
3. Zilberberg M.D., Shorr A.F., Kollef M.H. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg. Infect. Dis. 2008, 14:929-931.
4. Lessa F.C., Mu Y., Bamberg W.M., Beldavs Z.G., Dumyati G.K., Dunn J.R., et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 2015, 372:825-834.
5. Hecht D.W., Galang M.A., Sambol S.P., Osmolski J.R., Johnson S., Gerding D.N. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 2007, 51:2716-2719.
6. Pelaez T., Alcala L., Alonso R., Martin-Lopez A., Garcia-Arias V., Marin M., et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob. Agents Chemother. 2005, 49:1157-1159.
7. Goulding D., Thompson H., Emerson J., Fairweather N.F., Dougan G., Douce G.R. Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1. Infect. Immun. 2009, 77:5478-5485.
8. Cornely O.A., Nathwani D., Ivanescu C., Odufowora-Sita O., Retsa P., Odeyemi I.A. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J. Antimicrob. Chemother. 2014, 69:2892-2900.
9. Reynolds P.E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 1989, 8:943-950.
10. Knight R.C., Rowley D.A., Skolimowski I., Edwards D.I. Mechanism of action of nitroimidazole antimicrobial and antitumour radiosensitizing drugs. Effects of reduced misonidazole on DNA. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1979, 36:367-377.
11. Basseres E., Endres B.T., Khaleduzzaman M., Miraftabi F., Alam M.J., Vickers R.J., et al. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J. Antimicrob. Chemother. 2016, 71:1245-1251.
12. Macfarlane S., Macfarlane G.T. Composition and metabolic activities of bacterial biofilms colonizing food residues in the human gut. Appl. Environ. Microbiol. 2006, 72:6204-6211.
13. Haley K.P., Blanz E.J., Gaddy J.A. High resolution electron microscopy of the Helicobacter pylori Cag type IV secretion system pili produced in varying conditions of iron availability. J. Vis. Exp. 2014, e52122.
14. Corbett D., Wise A., Birchall S., Warn P., Baines S.D., Crowther G., et al. In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J. Antimicrob. Chemother. 2015, 70:1751-1756.
15. Odenholt I., Walder M., Wullt M. Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile. Chemotherapy 2007, 53:267-274.
16. Ransom E.M., Williams K.B., Weiss D.S., Ellermeier C.D. Identification and characterization of a gene cluster required for proper rod shape, cell division, and pathogenesis in Clostridium difficile. J. Bacteriol. 2014, 196:2290-2300.
17. Ransom E.M., Ellermeier C.D., Weiss D.S. Use of mCherry Red fluorescent protein for studies of protein localization and gene expression in Clostridium difficile. Appl. Environ. Microbiol. 2015, 81:1652-1660.
18. Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 2007, 45:302-307.
19. Artsimovitch I., Seddon J., Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin. Infect. Dis. 2012, 55(Suppl. 2):S127-S131.
20. Jeya M., Moon H.J., Lee K.M., Kim I.W., Lee J.K. Glycopeptide antibiotics and their novel semi-synthetic derivatives. Curr. Pharm. Biotechnol. 2011, 12:1194-1204.
21. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N. Engl. J. Med. 2008, 359:1932-1940.
22. Chilton C.H., Crowther G.S., Todhunter S.L., Ashwin H., Longshaw C.M., Karas A., et al. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. J. Antimicrob. Chemother. 2015, 70:2598-2607.
23. Alam M.Z., Wu X., Mascio C., Chesnel L., Hurdle J.G. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob. Agents Chemother. 2015, 59:5165-5170.